Researchers at Fred Hutchinson Cancer Center have made significant strides in combating Epstein-Barr virus (EBV), a virus that infects approximately 95% of the global population and is linked to various cancers and chronic diseases. Utilizing transgenic mice engineered to produce human antibodies, the team developed powerful monoclonal antibodies that effectively block EBV from attaching to and entering human immune cells. Notably, one of these antibodies completely prevented infection in lab models with human-like immune systems, marking a pivotal advancement in the ongoing battle against EBV’s pervasive ability to invade B cells.

The implications of these findings are profound, particularly for transplant patients, who are at heightened risk for EBV-related complications due to immunosuppressive therapies. Current treatment options to prevent post-transplant lymphoproliferative disorders (PTLD), which are often driven by uncontrolled EBV, are limited. The study highlights the potential of these newly identified antibodies targeting the viral proteins gp350 and gp42 to prevent EBV viremia, thereby reducing the incidence of PTLD and improving overall patient outcomes without necessitating a reduction in immunosuppression.

This research not only opens avenues for targeted therapies against EBV but also sets a precedent for developing protective antibodies against other pathogens. The successful identification of these antibodies could accelerate the timeline for clinical applications, with plans for safety testing in healthy adults and subsequent trials in high-risk populations. As the team moves forward with industry collaborations to bring these findings to clinical use, the potential for a transformative preventive therapy against EBV is within reach, promising to significantly impact transplant medicine and patient care.

Source: sciencedaily.com